Thursday, July 19, 2012

Biotech Stock Trading Alert: Sunshine Biopharma (OTCBB: SBFM) Trades up over 10% on News of Manufacturing Adva-27a

New York, New York –July 19, 2012 –(Investorideas.com Newswire,Biotechindustrystocks.com)     Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues a trading alert for Sunshine Biopharma Inc. (OTCBB: SBFM). The stock is trading
up over 10% on news of manufacturing Adva-27a.

The Company reported that it has engaged Beta Pharma Canada Inc. to manufacture an initial batch of Adva-27a and provide synthesis parameters for future scale-up and large scale manufacturing of the drug. Beta Pharma Canada Inc. is an affiliate of Beta Pharma Inc. with offices and facilities in Connecticut (USA) and Shanghai ( China). Beta Pharma Canada Inc., headquartered in Montreal ( Canada), is a Canadian small-molecule drug discovery and manufacturing company specializing in design, synthesis and process development of novel pharmaceutical compounds. Adva-27a is Sunshine Biopharma’s lead anti-cancer compound which has proven effective at killing Multidrug Resistant Breast Cancer cells (MCF-7/MDR) and Small-Cell Lung Cancer cells (H69AR).



Recent Q&A with Mr. Camille Sebaaly, CFO of Sunshine Biopharma Inc. (OTCBB: SBFM) at Investorideas.com
http://www.investorideas.com/CO/SBFM/news/2012/07021.asp

About Sunshine Biopharma Inc. (OTCBB: SBFM):
Sunshine Biopharma is a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. The Company’s lead compound, Adva-27a targets aggressive forms of cancer.
www.sunshinebiopharma.com


About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, including biotech and pharma stocks. Visit the biotech portal within Investor Ideas: www.biotechindustrystocks.com

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

 Sign up for the free investor news and biotech stock alerts

Research biotech stocks at the Investor Ideas Biotech stocks Directory

Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: A third party on behalf of SBFM compensated Investorideas.com for news release publishing and distribution: one hundred thousand 144 shares for three months starting June 26th
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

800-665-0411 - Source – www.Investorideas.com



Biotech Stock Alert: SUNSHINE BIOPHARMA (OTCBB:SBFM) ENGAGES BETA PHARMA CANADA FOR MANUFACTURING OF AN INITIAL BATCH OF Adva-27a

Montreal, Quebec, Canada - July 19, 2012 (Investorideas.com newswire) - Sunshine Biopharma Inc. (OTCBB:SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has engaged Beta Pharma Canada Inc. to manufacture an initial batch of Adva-27a and provide synthesis parameters for future scale-up and large scale manufacturing of the drug. Beta Pharma Canada Inc. is an affiliate of Beta Pharma Inc. with offices and facilities in Connecticut (USA) and Shanghai ( China). Beta Pharma Canada Inc., headquartered in Montreal ( Canada), is a Canadian small-molecule drug discovery and manufacturing company specializing in design, synthesis and process development of novel pharmaceutical compounds. Adva-27a is Sunshine Biopharma’s lead anti-cancer compound which has proven effective at killing Multidrug Resistant Breast Cancer cells (MCF-7/MDR) and Small-Cell Lung Cancer cells (H69AR).

"We are delighted to be working with Beta Pharma Canada with excellent in-house synthesis capability and can amass additional resources through its corporate affiliations", said Dr. Steve N. Slilaty, Sunshine’s President and CEO. "We anticipate delivery of the new batch of Adva-27a together with the synthesis parameters by the end of the month", he added.
About Sunshine Biopharma Inc. (OTCBB: SBFM):
Sunshine Biopharma is a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. The Company’s lead compound, Adva-27a targets aggressive forms of cancer.
www.sunshinebiopharma.com
Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
For Additional Information Contact:
Camille Sebaaly, CFO
Sunshine Biopharma Inc.
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
www.sunshinebiopharma.com
Published at Investorideas.com Newswire
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: A third party on behalf of SBFM compensated Investorideas.com for news release publishing and distribution: one hundred thousand 144 shares for three months starting June 26 th
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 www.Investorideas.com
Published at Investorideas.com newswire
Learn more about Sunshine Biopharma Inc. (OTCBB:SBFM): Profile
Disclaimer/ Disclosure: The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: A third party on behalf of SBFM compensates Investorideas.com for news release publishing and distribution : one hundred thousand 144 shares for three months starting June 26th
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Wednesday, July 18, 2012

OTC Beverage Stocks in the News: (PLSB), (AHFD), (DNAX)

New York, New York - July 18, 2012 (Investorideas.com newswire, www.beveragestocks.com) Investorideas.com, an investor research portal specializing in sector research including beverage stocks issues an alert for OTCBB listed beverage stocks in the news.

The Pulse Beverage Corporation (OTCBB:PLSB) makers of Cabana™ 100% Natural Lemonade and Pulse® NutriPurpose™ brand beverages, reported an update yesterday on growing its distribution territories through securing additional distributors. Pulse Beverage has added additional distribution in key territories which should drive its expected increase in case sales dramatically during Q3. The stock is currently trading at $0.53 on over 90,000 shares.
On July 10 th, Active Health Foods, Inc. (OTC: AHFD), the maker of "Active X™" 100% Organic Certified, 100% Natural, Kosher and Vegan Certified Energy Bars announced that the shareholders of Manos Beverages, Inc., the maker of All Natural Flavors™, a sparkling, flavored, "Sugar Free" beverage, has agreed to be acquired by Active Health Foods, Inc. The stock is currently trading down volume of 276,000 shares.
DNA Brands, Inc. (OTC: DNAX) announced in June that The Original Fast Food Company began distribution of DNA's Energy Drink® product on June 12, 2012, beginning in Tallahassee, Florida, to be then followed by Pensacola, Florida. The stock is trading at $0.1990 0.0190(10.56%) on light volume. The stock has a 52 week range of $0.1- $1.02.
Research beverage stocks with the beverage stocks directory at Investorideas.com and www.beveragestocks.com
http://www.investorideas.com/Beverage_Stocks/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; water and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, natural gas stocks, tech (includes cloud and social networking), defense stocks, nanotech, China stocks and agriculture.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Sign up for the free investor news and stock alerts http://www.investorideas.com/Resources/Newsletter.asp
Become an Investorideas.com Member
http://www.investorideas.com/membership/
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411
Source - www.Investorideas.com

Pharma and Biotech Stock Trading Alert; Supernus (NASDAQ:SUPN) Trades up over 17%

New York, New York - July 18, 2012 (Investorideas.com Newswire) Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues a trading alert for Supernus Pharmaceuticals, Inc. (NasdaqGM :SUPN) trading up at $12.58, gaining $1.89 or 17.68% 10:35AM EDT on 176,000 shares . The stock is the morning leader on NASDAQ percentage gainers.
The most recent news from the Company was Friday, when it provided an update on the launch of its two epilepsy products; Trokendi XR(TM) and SPN-804.
Investorideas.com Newswire Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system, or CNS, diseases. The company is developing several product candidates in neurology and psychiatry to address large market opportunities in epilepsy and ADHD including ADHD patients with impulsive aggression. These product candidates include Trokendi XR (extended-release topiramate), formerly known as SPN-538, and SPN-804 (extended-release oxcarbazepine) for epilepsy, SPN-810 for impulsive aggression in ADHD and SPN-812 for ADHD.

About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; water and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, natural gas stocks, tech (includes cloud and social networking), defense stocks, nanotech,   China  stocks and agriculture.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Sign up for the free investor news and stock alerts http://www.investorideas.com/Resources/Newsletter.asp
Research biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
Become an Investorideas.com Member
http://www.investorideas.com/membership/
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook a href="http://www.facebook.com/Investorideas"> http://www.facebook.com/Investorideas
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source - www.Investorideas.com

Tuesday, July 17, 2012

Cleantech Stock Alert: Fuel-Tech (NasdaqGS: FTEK) Spikes on $36.6 Million Air Pollution Control contract in Chile

July 17, 2012 (Investorideas.com renewable energy/ green newswire) Investorideas.com, a leader in renewable energy stock research for independent investors, issues an investor alert for Fuel-Tech, Inc. (NasdaqGS :FTEK), trading at $5.3450, gaining 0.7750 or 16.96% as of 11:36AM EDT, moving on news of a $36.6 Million Air Pollution Control contract in Chile.

According to the Company, "The $36.6 million order, placed by E.CL S.A., a major utility in Chile, includes turnkey installation of Low NOx Burners (LNBs) and Over-Fire Air (OFA) systems and mill modernization for six coal-fired units. Equipment deliveries are scheduled to commence during the first quarter of 2013, with project completion occurring during the third quarter of 2014."
Investorideas.com Newswire About Fuel Tech
Fuel Tech is a leading technology company engaged in the worldwide development, commercialization and application of state-of-the-art proprietary technologies for air pollution control, process optimization, and advanced engineering services. These technologies enable customers to produce both energy and processed materials in a cost-effective and environmentally sustainable manner.
Research more cleantech stocks on global stock exchanges -and up to 1400 at Investorideas.com renewable energy stocks stock directory
About Investorideas.com - a leader in cleantech investor research
www.Investorideas.com was on the of the first investor sites covering investing in water and renewable energy stocks and has become a global go-to destination for investors researching the cleantech sector, with stock directories, company news, commentary from experts, research reports and industry resources and links. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.
Follow Investorideas.com on Twitter
Follow Investorideas.com on Facebook
Follow Investorideas.com on Google Plus
Follow Renewable Energy Stocks on Facebook.com
Sign Up: Get Free investor news and stock alerts
Join Investor Ideas Get 24/7 Login to 13 of the best stock directories online;
Research oil and gas stocks, gold stocks, water stocks, renewable energy stocks, tech and more.
Disclaimer/ Disclosure: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and its management and is not the opinion of Investorideas.com. Learn more: www.InvestorIdeas.com/About/Disclaimer.asp Investorideas.com was not compensated for this report and does not hold a position in the stock
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
For more information about Investorideas.com
contact:
800.665.0411

Tech Stock Trading News Alert; CSR (NASDAQ:CSRE) Leads NASDAQ Top Percentage Gainers

New York, NY - July 17, 2012 (InvestorIdeas.com Newswire) Investor Ideas, www.InvestorIdeas.com, a global investor research portal for independent investors, issues a tech stock trading alert for CSR plc (LSE: CSR; NASDAQ: CSRE), the top percentage gainer in morning trading in the NASDAQ. The stock is trading at $18.10, gaining $ 4.54 or 33.48% on relatively light volume of 78,000 shares.
The Company reported news today of a proposed transfer of CSR's Handset connectivity and location development operations and technology to Samsung for US$310 million in cash.
Investorideas.com Newswire About CSR
CSR is a global provider of innovative silicon and software solutions for the location-aware, media-rich, cloud-connected world. Our platforms are optimised for the automotive navigation and infotainment, digital cameras and imaging, connected home infotainment and wireless audio markets. We provide solutions to complex problems in the audio-visual, connectivity and location technology domains across a broad range of markets, with a technology portfolio that includes GPS/GNSS systems, Bluetooth®, Wi-Fi®, FM, NFC, aptX® and CVCTM audio codecs, JPEG, MPEG, H.264 imaging, PDL printing, microcontrollers, DSPs and broadband receivers. CSR's technology solutions and market platforms enable its customers to deliver a superior user experience and are adopted by leaders in the auto, computer, home and mobile markets. www.csr.com
About Investorideas.com

InvestorIdeas.com is a leader in investor stock research with a focus on energy and water. Sectors we cover include; water and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, natural gas stocks, tech (includes cloud and social networking), defense stocks, nanotech, China stocks and agriculture.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook
http://www.facebook.com/Investorideas
Get Free investor news and stock alerts
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas Get 13 of the best stock directories online;
Research tech stocks, oil and gas stocks, gold stocks, water stocks, renewable energy stocks and more
Join: http://www.investorideas.com/membership/
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising . www.InvestorIdeas.com/About/Disclaimer.asp
800-665-0411 - Source - www.Investorideas.com

Nanotechnology Stocks; Stevens Institute of Technology and mPhase (OTC.BB:XDSL) to Partner on Research and Business Opportunities

LITTLE FALLS, NJ - July 17, 2012 (Investorideas.com Newswire) - mPhase Technologies, Inc. (OTC.BB: XDSL.OB) and Stevens Institute of Technology have announced an official agreement to jointly pursue business opportunities with government and industry as well as research and development (R&D) projects.

Specifically, Stevens and mPhase will collaborate on the design and fabrication of an advanced battery technology utilizing intellectual property and know-how from both parties with the possibility of integrating and advancing mPhase's Smart NanoBattery Technology with Stevens' graphene-based inkjet printing method for printing electrodes and electronic circuits.

The parties also wish to explore the possibility of funding Stevens' research activities relative to graphene-based research projects to advance the inkjet printing of electronics utilizing advanced materials

"mPhase is excited to explore the possibilities of integrating Stevens' leading position in the inkjet printing of energy storage devices using graphene with mPhase's Smart NanoBattery Technology," said Ronald A. Durando, CEO of mPhase Technologies.

"Stevens looks forward to continuing its relationship with mPhase by pursuing this exciting opportunity," added Christos Christodoulatos, Associate Provost of Stevens, Office of Academic Entrepreneurship.

About mPhase Technologies, Inc.

mPhase Technologies is introducing a revolutionary Smart Surface technology enabled by breakthroughs in nanotechnology, MEMS processing and microfluidics. Our Smart Surface technology has potential applications within drug delivery systems, lab-on-a-chip analytic systems, self-cleaning systems, liquid and chemical sensor systems, and filtration systems. mPhase has pioneered its first Smart Surface enabled product, the mPhase Smart NanoBattery. In addition to the Smart Surface technology, mPhase recently introduced its first product, the mPower Emergency Illuminator, an award-winning product designed by Porsche Design Studio and sold via the mPower website: http://www.mPhaseTech.com.

More information about the company can be found at http://www.mPhaseTech.com.

About Stevens Institute of Technology

Founded in 1870, Stevens Institute of Technology, The Innovation University™, lives at the intersection of industry, academics and research. The University's students, faculty and partners leverage their collective real-world experience and culture of innovation, research and entrepreneurship to confront global challenges in engineering, science, systems and technology management.

Based in Hoboken, N.J. and with a location in Washington, D.C., Stevens offers baccalaureate, master's, certificates and doctoral degrees in engineering, the sciences and management, in addition to baccalaureate degrees in business and liberal arts. Stevens has been recognized by both the US Department of Defense and the Department of Homeland Security as a National Center of Excellence in the areas of systems engineering and port security research. The University has a total enrollment of more than 2,400 undergraduate and 3,700 graduate students with more than 450 faculty. Stevens' graduate programs have attracted international participation from China, India, Southeast Asia, Europe and Latin America as well as strategic partnerships with industry leaders, governments and other universities around the world. Additional information may be obtained at www.stevens.edu and www.stevens.edu/news.

Forward-Looking Statements: As a cautionary note to investors, certain matters discussed in this press release may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such matters involve risks and uncertainties that may cause actual results to differ materially, including the following: changes in economic conditions; general competitive factors; acceptance of the Company's products in the market; the Company's success in technology and product development; the Company's ability to execute its business model and strategic plans; and all the risks and related information described from time to time in the Company's SEC filings, including the financial statements and related information contained in the Company's SEC Filing. mPhase assumes no obligation to update the information in this release.

Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=2038816

Forward-Looking Statements

As a cautionary note to investors, certain matters discussed in this press release may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such matters involve risks and uncertainties that may cause actual results to differ materially, including the following: changes in economic conditions; general competitive factors; acceptance of the Company's products in the market; the Company's success in technology and product development; the Company's ability to execute its business model and strategic plans; and all the risks and related information described from time to time in the Company's SEC filings, including the financial statements and related information contained in the Company's SEC Filing. mPhase assumes no obligation to update the information in this release.

Contact:

973-256-3737
mPhase Technologies, Inc.

Visit the XDSL showcase profile at Investorideas.com
Request News and Info on XDSL
Disclosure, Disclaimer/ XDSL is a paid advertising client on Investorideas.com and our technology portals.

Monday, July 16, 2012

Biofuel Energy Stock Alert: BioFuel Energy (NASDAQ: BIOF) Spikes over 24%

New York, NY - July 16, 2012 (Investorideas.com renewable energy/ green newswire) Investorideas.com, a leader in renewable energy stock research for independent investors, issues an investor alert for BioFuel Energy Corp. (NasdaqCM :BIOF), trading up at $3.09, gaining $0.60 or 24.29% as of 12:24PM EDT on over 244,000 shares.
The stock is rebounding following a loss in Friday’s trading session.
he most recent news from the company was late June when it announced a collaboration with Gevo, Inc. (GEVO), a leading renewable chemicals and next-generation biofuels company, to explore high-volume production of isobutanol.
Investorideas.com Newswire About Biofuel Energy
Headquartered in Denver, Colo., the company operates two 110 MGPY ethanol production facilities in Fairmont, Minn. and Wood River, Neb.
Research more cleantech stocks on global stock exchanges -and up to 1400 at Investorideas.com renewable energy stocks stock directory
About Investorideas.com - a leader in cleantech investor research

www.Investorideas.com was on the of the first investor sites covering investing in water and renewable energy stocks and has become a global go-to destination for investors researching the cleantech sector, with stock directories, company news, commentary from experts, research reports and industry resources and links. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.
Follow Investorideas.com on Twitter
Follow Investorideas.com on Facebook
Follow Investorideas.com on Google Plus
Follow Renewable Energy Stocks on Facebook.com
Sign Up: Get Free investor news and stock alerts
Join Investor Ideas Get 24/7 Login to 13 of the best stock directories online;
Research oil and gas stocks, gold stocks, water stocks, renewable energy stocks, tech and more.
Disclaimer/ Disclosure : Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and its management and is not the opinion of Investorideas.com. Learn more: www.InvestorIdeas.com/About/Disclaimer.asp Investorideas.com was not compensated for this report and does not hold a position in the stock
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
For more information about Investorideas.com
contact:
800.665.0411

Biopharma Stock Trading Alert: Alnylam (NASDAQ:ALNY) Leads NASDAQ Top Gainers on News of Positive ALN-TTR02 Clinical Data

New York, New York - July 16, 2012 (Investorideas.com Newswire) Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues a trading alert for Alnylam Pharmaceuticals, Inc. (NasdaqGS :ALNY), trading at $16.05, up $3.53 or 28.19%) as of 11:04AM EDT on over 2 Million shares. As of the time of this report, ALNY was the top percentage gainer on the NASDAQ.
The Company reported news today of the achievement of positive clinical results from its Phase I trial with ALN-TTR02, an RNAi therapeutic targeting the transthyretin (TTR) gene for the treatment of TTR-mediated amyloidosis (ATTR).
Investorideas.com Newswire About Alnylam Pharmaceuticals
Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is leading the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases, including ALN-TTR for the treatment of transthyretin-mediated amyloidosis (ATTR), ALN-AT3 for the treatment of hemophilia, ALN-PCS for the treatment of severe hypercholesterolemia, ALN-HPN for the treatment of refractory anemia, and ALN-TMP for the treatment of hemoglobinopathies. As part of its “Alnylam 5x15TM” strategy, the company expects to have five RNAi therapeutic products for genetically defined diseases in clinical development, including programs in advanced stages, on its own or with a partner by the end of 2015. Alnylam has additional partnered programs in clinical or development stages, including ALN-RSV01 for the treatment of respiratory syncytial virus (RSV) infection, ALN-VSP for the treatment of liver cancers, and ALN-HTT for the treatment of Huntington's disease. The company's leadership position on RNAi therapeutics and intellectual property have enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, Biogen Idec, Roche, Takeda, Kyowa Hakko Kirin, Cubist, and Ascletis. In addition, Alnylam and Isis co-founded Regulus Therapeutics Inc., a company focused on discovery, development, and commercialization of microRNA therapeutics; Regulus has formed partnerships with GlaxoSmithKline and Sanofi. Alnylam has also formed Alnylam Biotherapeutics, a division of the company focused on the development of RNAi technologies for applications in biologics manufacturing, including recombinant proteins and monoclonal antibodies. Alnylam's VaxiRNA™ platform applies RNAi technology to improve the manufacturing processes for vaccines; GlaxoSmithKline is a collaborator in this effort. Alnylam scientists and collaborators have published their research on RNAi therapeutics in over 100 peer-reviewed papers, including many in the world's top scientific journals such as Nature, Nature Medicine, Nature Biotechnology, and Cell. www.alnylam.com.

About InvestorIdeas.com:
www.InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; water and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, natural gas stocks, tech (includes cloud and social networking), defense stocks, nanotech,   China  stocks and agriculture.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Sign up for the free investor news and stock alerts at Investorideas.com
Research biotech stocks at the Biotech stocks Directory and biotech news and research at www.biotechindustrystocks.com
Become an Investorideas.com Member
http://www.investorideas.com/membership/
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411
Source - www.Investorideas.com

Biotech stocks News; A Tale of Two Biotech Companies: Q&A With Roche (SIX: RO, ROG; OTCQX: RHHBY) and Sunshine Biopharma (OTCBB: SBFM) Discussing Lead Cancer Products

NEW YORK, NY - July 16, 2012 (Investorideas.com newswire) - InvestorIdeas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues a Q&A snapshot of two biotech companies taking aim at aggressive forms of cancer; Roche (SIX:RO) (ROG.VX) (RHHBY) (RHHBY) with its Herceptin® cancer drug and Sunshine Biopharma Inc. (SBFM) with its lead compound, Adva-27a.

The interview(s) gives investors insight into how a small biotech company, Sunshine Biopharma, plans to target the cancer drug market of the future with its technology and collaborations and the historical path of the largest biotech company in the world bringing Herceptin to market, reaching sales of over $5 billion in 2010.
Roche (SIX: RO, ROG; OTCQX: RHHBY) /Genetech’s Herceptin:
Q: Investorideas.com staff:
When was the licensing agreement put in place with Genentech and Roche for Herceptin®?
A: Nina Goworek, Investor Relations Officer for Roche
Genentech and Roche signed a licensing agreement giving Roche exclusive marketing rights for Herceptin outside of the US in July 1998
Q: Investorideas.com staff:
What other cancers are targeted with Herceptin® other than HER2-positive breast cancer and what FDA approvals are in place?
A: Nina Goworek, Investor Relations Officer for Roche
In the US:
September 1998 - Herceptin is approved for 1st-line Her2 positive metastatic breast cancer in combination with chemotherapy (paclitaxel) and also approved as a medicine to be used alone for women who had received prior chemotherapy (second- and third-line treatment),
November 2006 - Herceptin is approved for adjuvant or early stage HER2 positive breast cancer when given with chemotherapy (doxorubicin, cyclophosphamide and paclitaxel), a combination called AC-TH
January 2008 - approved as a stand-alone medicine following anthracycline-based chemotherapy
May 2008 - Herceptin and chemotherapy (docetaxel and carboplatin), known as TCH, was approved; Another AC-TH combination, comprised of Herceptin, doxorubicin, cyclophosphamide and docetaxel, was also approved
October 2010 - Herceptin is approved in combination with cisplatin and capecitabine or 5-fluorouracil, for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma, who have not received prior treatment for metastatic disease (1st-line)
Q: Investorideas.com staff:
The Company recently announced in June the FDA approved for Perjeta in combination with Herceptin- how does this combination improve results?
A; Nina Goworek, Investor Relations Officer for Roche
The addition of Perjeta in combination with Herceptin plus docetaxel (chemo) showed an increase of progression free survival (PFS) from a median of 12.4 months to 18.5 months - an increase of 6.1months. Statistically significant overall survival top-line results were announced with the data to be presented at an upcoming medical meeting.
Q: Investorideas.com staff:
What is the current number of women with HER2-positive breast cancer have been treated with Herceptin?
A; Nina Goworek, Investor Relations Officer for Roche
As of January 2012, there were roughly 440,000 patients treated with Herceptin in the US for all indications and more that 1.2 million people have been treated with Herceptin globally.
Sunshine Biopharma Inc. (OTCBB: SBFM) and Adva-27a
Q: Investorideas.com
Can you give us a brief history of the development of Adva-27a?
A: Mr. Camille Sebaaly, CFO of Sunshine Biopharma Inc
Adva-27a is a small molecule which we designed and synthesized de novo. The patents covering Adva-27a and derivatives in the United States and Europe have issued recently. Various patents in other places around the world are still pending. Adva-27a was designed to specifically target multidrug resistant (or aggressive) types of cancer.
Q: Investorideas.com staff
From your recent press releases you now have data on both lung and breast cancer results for Adva-27a, potentially doubling the market potential. Can you give investors a brief summary of the results to date?
A: Mr. Camille Sebaaly, CFO of Sunshine Biopharma Inc.
There are different types of transporter proteins which when overexpressed make cancer cells resistant to drugs. Different multidrug resistant cancer types may overexpress different transporter proteins. Our data to date have shown that Adva-27a can overcome two multidrug resistance proteins: MDR1 and MRP1 as present in the breast cancer cells and the lung cancer cells we tested. Lung and breast cancer are the two most frequently encountered cancers in humans.
Q: Investorideas.com staff
How do your collaborations withthe State University of New York at Binghamton and McGill University’s Jewish General Hospital in Montreal ( Canada) help you take Adva-27a to clinical trials?
A: Mr. Camille Sebaaly, CFO of Sunshine Biopharma Inc
We are delighted for the help, dedication and contribution of these two of the finest institutions in the world. They have and continue to be of great help to us in our efforts to put Adva-27a through the drug development stages. We anticipate that our first clinical trial will be done at the Jewish General Hospital on breast cancer volunteers.
Q: Investorideas.com staff
For investors looking at a small biotech company like yours, taking on the big pharma companies, how do you address the massive financial and corporate undertaking of bringing Adva-27a to market?
A: Mr. Camille Sebaaly, CFO of Sunshine Biopharma Inc
It is indeed very costly to bring a drug to market. We have been fortunate in our financing efforts to date and we hope to be able to continue to access the private and public markets for funding on an as needed basis to continue the development of our flagship Adva-27a and bring it to market for cancer sufferers around the world.
Q: Investorideas.com staff
Do you have any third party projections for the market potential ofAdva-27a?
A: Mr. Camille Sebaaly, CFO of Sunshine Biopharma Inc
We have not commissioned any one to do projections of market potential of our Adva-27a. However, we do know that important cancer drugs generally reach annual sales of about $1 billion within 1 to 2 years of FDA approval. We believe Adva-27a will have a similar sales profile.
About Sunshine Biopharma Inc. (OTCBB: SBFM):
Sunshine Biopharma is a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. The Company’s lead compound, Adva-27a targets aggressive forms of cancer.
www.sunshinebiopharma.com
About Roche (SIX: RO, ROG; OTCQX: RHHBY):
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2011, Roche had over 80,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 42.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan.
www.roche.com
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, including biotech and pharma stocks. Other sectors include renewable energy, oil and gas, mining and tech stocks.
Visit the biotech portal within Investor Ideas: www.biotechindustrystocks.com
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Sign up for the free investor news and biotech stock alerts
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: A third party on behalf of SBFM compensated Investorideas.com for news release publishing and distribution: one hundred thousand 144 shares for three months starting June 26 th
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411
Source - www.Investorideas.com
Published at Investorideas.com newswire
Learn more about Sunshine Biopharma Inc. (OTCBB:SBFM): Profile
Disclaimer/ Disclosure: The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: A third party on behalf of SBFM compensates Investorideas.com for news release publishing and distribution : one hundred thousand 144 shares for three months starting June 26th
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Friday, July 13, 2012

Solar Energy Stock Trading News Alert; EMCORE (NASDAQ: EMKR) Soars 11%

New York, NY - July 13, 2012 (Investorideas.com renewable energy/ green newswire) Investorideas.com news staff: Investorideas.com, a leader in renewable energy stock research for independent investors, issues a trading alert for solar stock EMCORE (NASDAQ: EMKR), trading up at $4.74, gaining $ 0.49 or 11.53% as of 11:48AM EDT on over 140,000 shares.
Earlier this week the Company announced that it had achieved the Company's 100th successful satellite launch and deployment with primary power supplied by EMCORE solar cells or solar panels.
The stock also just received coverage initiated by FBR Capital (outperform).
Investorideas.com Newswire About EMCORE
EMCORE Corporation offers a broad portfolio of compound semiconductor-based products for the fiber optics and solar power markets. EMCORE's Fiber Optics business segment provides optical components, subsystems and systems for high-speed telecommunications, Cable Television (CATV) and Fiber-To-The-Premise (FTTP) networks, as well as products for satellite communications, video transport and specialty photonics technologies for defense and homeland security applications. EMCORE's Solar Photovoltaics business segment provides products for both space and terrestrial solar power applications. For space applications, EMCORE offers high-efficiency multi-junction solar cells, Covered Interconnect Cells (CICs) and complete satellite solar panels. For terrestrial applications, EMCORE offers a broad portfolio of Concentrator Photovoltaic (CPV) multi-junction solar cells and components, as well as commercial rooftop solar concentrator systems. http://www.emcore.com.
Research more solar stocks on global stock exchanges - and up to 1400 renewable energy stocks at Investorideas.com http://www.investorideas.com/ Companies/ RenewableEnergy/ Stock_List.asp
About Investorideas.com - a leader in cleantech investor research
Investorideas.com was on the of the first investor sites covering investing in water and renewable energy stocks and has become a global go-to destination for investors researching the cleantech sector, with stock directories, company news, commentary from experts, research reports and industry resources and links. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Renewable Energy Stocks onFacebook.com
http://www.facebook.com/renewableenergystocks
Get Free investor news and stock alerts
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas Get 24/7 Login to 13 of the best stock directories online;
Research oil and gas stocks, gold stocks, water stocks, renewable energy stocks, tech and more. Join: http://www.investorideas.com/membership/
Disclaimer/ Disclosure: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and its management and is not the opinion of Investorideas.com. Learn more: www.InvestorIdeas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
For more information about Investorideas.com
contact:
800.665.0411

Junior Gold Stock News; Evolving Gold (TSX: EVG) Makes List of Top Percentage Gainers on TSX

New York, NY - July 13, 2012 (Investorideas.com Newswire) Investor Ideas, www.InvestorIdeas.com, a global investor research portal for independent investors, issues a trading alert for junior gold stock, Evolving Gold (TSX: EVG), trading up at $0.34, gaining 0.08 or (28.30%) as 10:56AM EDT. EVG is one of the top percentage gainers on the TSX in morning trading.
On July 11 the Company reported that diamond drill hole CAR-016.1 intersected several high grade gold zones at its Carlin Project in Nevada, including 9.1 meters at 22.0 gpt (grams per tonne) gold (30.0 feet at 0.64 ounces per ton, opt gold) starting at 908.3 meters down hole. This intersection includes 1.2 meters at 44.0 gpt gold (4.0 feet at 1.28 opt gold). In addition CAR-016.1 intersected 1.2 meters at 15.5 gpt gold (4.0 feet at 0.45 opt gold) starting at 897.9 meters down hole. The entire interval from 897.9 to 917.4 (19.5 meters or 64.0 feet) averages 11.76 gpt gold (0.34 opt gold), including a lower grade interval at 899.2-908.3 meters.
Carlin Drill Map: http://www.evolvinggold.com/properties/carlin/map.html
About Evolving Gold Corp.
Evolving Gold is focused on exploring its gold properties in and adjacent to the productive Carlin district of northern Nevada, and its gold discovery at Rattlesnake Hills, Wyoming.
www.evolvinggold.com.
Investorideas.com Newswire About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, including biotech and pharma stocks. Visit the biotech portal within Investor Ideas: www.biotechindustrystocks.com
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Sign up for the free investor news and stock alerts
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411
Source - www.Investorideas.com

Thursday, July 12, 2012

Biopharma Stock Trading Investor Alert: Affymax (NASDAQ:AFFY) Leads NASDAQ Top Percentage Gainers on News of Supply Agreement for OMONTYS

New York, NY - July 12, 2012 (Investorideas.com Newswire) Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues an alert for Affymax, Inc. (NasdaqGS: AFFY), trading at $13.30, gaining $1.34 or 11.20% as of 11:03AM EDT on over 1.5 Million shares. The stock had a morning high of $13.71 and is currently the top percentage gainer on the NASDAQ.
The Company today reported that Takeda Pharmaceuticals America, Inc. (TPA) has entered into a supply agreement for sourcing and supply of OMONTYS (peginesatide) Injection to Fresenius Medical Care North America and certain of its affiliates. OMONTYS is the only once-monthly erythropoiesis-stimulating agent (ESA) for anemia available to the dialysis patient population with chronic kidney disease (CKD) in the United States.
Investorideas.com Newswire About Affymax, Inc. (NasdaqGS: AFFY)
Affymax, Inc. is a biopharmaceutical company based in Palo Alto, California. Affymax’s mission is to discover, develop and deliver innovative therapies that improve the lives of patients with kidney disease and other serious and often life-threatening illnesses. The company’s first marketed product, OMONTYS, was approved by the U.S. Food and Drug Administration (FDA) in March 2012. www.affymax.com.
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; water and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, natural gas stocks, tech (includes cloud and social networking), defense stocks, nanotech, China stocks and agriculture.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Sign up for the free investor news and stock alerts at Investorideas.com
Research biotech and pharma stocks at the Biotech stocks Directory
Become an Investorideas.com Member
http://www.investorideas.com/membership/
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411
Source - www.Investorideas.com

Wednesday, July 11, 2012

Biopharma Stocks Reporting on Lung Cancer Developments: Sunshine Biopharma (OTCBB: SBFM), OncoGenex (NASDAQ: OGXI)

New York, New York - July 11, 2012 - Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues a snapshot of recent news from biopharma stocks reporting developments for the treatment of lung cancer. Sunshine Biopharma Inc. (OTCBB: SBFM) reported news on its lead compound, Adva-27a and OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced an update on its lead product, custirsen.
According to OncoGenex's press release, "Lung cancer is the second most common cancer in both men and women and the leading cause of cancer-related death. Each year, more people die of lung cancer than of colon, breast, and prostate cancers combined. This year, in the United States alone, approximately 226,160 new cases of lung cancer will be diagnosed and an estimated 160,340 patients will die of the disease. "
Sunshine Biopharma Inc. (OTCBB: SBFM) recently reported that it completed a cytotoxicity study of its lead compound, Adva-27a, in H69AR, a Multidrug Resistant Small Cell Lung Cancer cell line. Cytotoxicity studies measure the ability of a drug to destroy cancer cells in vitro. The results of the study showed that Adva-27a is significantly more effective at killing Multidrug Resistant Small Cell Lung Cancer cells than Etoposide, the current commonly used drug for this type of cancer.
Since reporting its news Sunshine Biopharma stock has more than doubled in recent trading and is currently trading at $0.54.
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) reported news yesterday on the clinical development program for custirsen and its plans to initiate a Phase 3 clinical trial in non-small cell lung cancer (NSCLC).The trial, planned to begin enrollment later this year, will evaluate the potential survival benefit of combining custirsen with docetaxel, a standard second-line chemotherapy treatment used in patients who have progressed after initial, or first-line, treatment has failed.
The Phase 3 trial will be an international, randomized, open-label study that will enroll approximately 1,100 patients with advanced or metastatic NSCLC who have been previously treated with a first-line platinum-based chemotherapy. Patients will be randomized to receive custirsen plus docetaxel or docetaxel alone. The primary objective of the study will be overall survival with additional secondary and exploratory analyses of other efficacy outcomes and biomarker relationships. Two formal interim analyses are planned for stopping the trial early based on inadequate evidence of clinical benefit or futility. No interim analyses for claiming efficacy are planned.
Custirsen, its lead product, is designed to block production of clusterin, a cell survival protein that is commonly overexpressed in several cancer types and in response to anticancer treatments.
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) is trading at $14.46, up 0.20 (1.40%) at the time of this report, with a morning high of $14.58.
About Sunshine Biopharma Inc. (OTCBB: SBFM):
Sunshine Biopharma is a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. The Company's lead compound, Adva-27a targets aggressive forms of cancer.
www.sunshinebiopharma.com
Investorideas.com Newswire About OncoGenex Pharmaceuticals (NASDAQ: OGXI)
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) have entered a global collaboration and license agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer. OGX-427 is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development. www.OncoGenex.com.
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, including biotech and pharma stocks. Visit the biotech portal within Investor Ideas: www.biotechindustrystocks.com
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Sign up for the free investor news and biotech stock alerts
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: A third party on behalf of SBFM compensated Investorideas.com for news release publishing and distribution: one hundred thousand 144 shares for three months starting June 26 th
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411
Source - www.Investorideas.com
Published at Investorideas.com newswire
Learn more about Sunshine Biopharma Inc. (OTCBB:SBFM): Profile
Disclaimer/ Disclosure: The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: A third party on behalf of SBFM compensates Investorideas.com for news release publishing and distribution : one hundred thousand 144 shares for three months starting June 26th
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Medical Technology Stock; Kallo (OTCBB: KALO) Announces Distribution Areas

MARKHAM, Ontario - July 11, 2012 (Investorideas.com newswire) - Kallo, Inc. (OTCBB:KALO) is excited to announce that the Government of Ghana has extended an invitation to Kallo to visit Accra , Ghana on the 23rd of July for final discussions for approval of distribution and operation of Kallo's Mobile Care Clinics.
Kallo's Mobile Care Clinics allow physicians to provide mobile services to rural areas where people have difficulty traveling to receive care.
"In the remote areas of Ghana , our Mobile Care clinics will be lifesaving. We are delighted at the response we have received and are extremely excited about our engineering and clinical team being invited by Ghana's Minister of Health for final discussions on the eHealth & Mobile Care program for the country," said John Cecil , Chairman and CEO of Kallo, Inc.
"As we prepare to travel to Accra , Ghana , we look forward to similar responses from other countries that we are negotiating with. We are delighted that the government of Ghana has decided to take this step in the interest of its people; the citizens of Ghana are on the verge of experiencing advanced HealthCare, not experienced before," concluded Mr. Cecil.
ABOUT Kallo, Inc.
Kallo, Inc., a medical information company, engages in the manufacturing and development of software that assists physicians and nurses to streamline patient information. Its software solution includes Electronic Medical Record software (EMR) and connectivity software that gathers medical information from various sources and deposits it into a single source as an electronic medical record for each patient.
Kallo, Inc. is a publicly traded company, listed on the OTC markets, (otcmarkets.com) stock symbol KALO.OB
Safe Harbor Statement:
This release includes forward-looking statements. These forward-looking statements generally can be identified by phrases such as INCL or its management "believes," "expects," "anticipates," "foresees," "forecasts," "estimates" or other words or phrases of similar import. Similarly, statements herein that describe the Company's business strategy, outlook, objectives, plans, intentions or goals also are forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.
Media contact:
John Cecil or Vince Leitao
416-246-9997
http://www.kalloinc.ca/
SOURCE: Kallo Inc.
Published at Investorideas.com Newswire
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. www.InvestorIdeas.com/About/Disclaimer.asp Disclosure: Compensation: Kallo Inc. (OTCBB: KALO) three thousand five hundred and 200,000 144 shares by a third party for news publishing, syndication, email distribution
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Tuesday, July 10, 2012

Biotech Stock Trading Alert: BioMimetic Therapeutics (NASDAQ: BMTI) Makes NASDAQ Top Percentage Gainer

New York, New York - July 10, 2012 (Investorideas.com Newswire) Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues a trading alert for BioMimetic Therapeutics Inc. (NasdaqGS :BMTI), trading at $3.38, up $ 0.58 (20.72%) 11:33AM on over 1 Million shares, making it the morning top percentage gainer on NASDAQ. The stock has a morning high of $3.56.
The Company reported yesterday it has submitted to the Food and Drug Administration (FDA) an amendment to its Pre-Market Approval (PMA) application for Augment® Bone Graft for its use as an alternative to autograft in hindfoot and ankle fusion procedures.
Investorideas.com Newswire About BioMimetic Therapeutics
BioMimetic Therapeutics (BMTI) is a biotechnology company specializing in the development and commercialization of clinically proven products to promote the healing of musculoskeletal injuries and diseases, including therapies for orthopedics, sports medicine and spine applications. All Augment® branded products are based upon recombinant human platelet-derived growth factor (rhPDGF-BB), which is an engineered form of PDGF, one of the body's principal agents to stimulate and direct healing and regeneration. Through the commercialization of this patented technology, BioMimetic seeks to become the leading company in the field of regenerative medicine by providing new treatment options for the repair of bone, cartilage, tendons and ligaments.
BioMimetic has received regulatory approvals to market Augment® Bone Graft in Canada, Australia and New Zealand for use in foot and ankle fusion indications. Augment is pending regulatory decisions in the U.S. and European Union for similar indications. The Company also markets a bone graft substitute line of products for orthopedic indications called AugmatrixTM Biocomposite Bone Graft.
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Sign up for the free investor news and stock alerts http://www.investorideas.com/Resources/Newsletter.asp
Research biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
Become an Investorideas.com Member
http://www.investorideas.com/membership/
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411
Source - www.Investorideas.com